


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A compound of the formula :



wherein:

Cy is independently a cyclyl group;

Q¹ is independently a covalent bond or cyclyl leader group;

the piperazin-1, 4-diyl group is optionally substituted;

J¹ is independently a covalent bond or -C(=O)- ;

J² is independently -C(=O)- or -S(=O)₂- ;

Q² is independently an acid leader group;

wherein:

Cy is independently:

C₃-₂₀carbocyclyl,

C₃-₂₀heterocyclyl, or

C₅-₂₀aryl;

and is optionally substituted;

Q¹ is independently:

a covalent bond;

C₁-₇alkylene; or

C₁-₇alkylene-X-C₁-₇alkylene, -X-C₁-₇alkylene, or C₁-₇alkylene-X-,

wherein X is -O- or -S-;

and is optionally substituted;

Q² is independently:

C₄-₈alkylene;

WATKINS et al.
Appl. No.: To Be Assigned
US National Phase of PCT/GB03/01463
September 30, 2004

and is optionally substituted;
and has a backbone length of at least 4 atoms;

or:

Q² is independently:

C₅₋₂₀arylene;

C₅₋₂₀arylene-C₁₋₇alkylene;

C₁₋₇alkylene-C₅₋₂₀arylene; or,

C₁₋₇alkylene-C₅₋₂₀arylene-C₁₋₇alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or a pharmaceutical acceptable salt, solvate, amide, ester, ether, chemically
protected form, or prodrug thereof.

Claims 2-79. (canceled).